Italfarmaco Touts Positive Results in Phase III DMD Trial Ahead of PDUFA

In advance of a March 21 PDUFA date, Italfarmaco on Tuesday reported that its drug candidate givinostat met the primary endpoint for treating Duchenne muscular dystrophy.